Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
All >

Deals > Northern Europe

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Northern Europe or involving organisations from these countries.

Total search results: 3076 | Ordered by Date (descending)
1 2 3 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Yukin Therapeutics–Medicxi: investment, 201906 financing round totalling €3.3m incl new + co-lead investor Medicxi 2019-06-04
Verdel Instruments–Longwall Venture Partners: investment, 201905 seed financing round totalling £230k incl £100k from Longwall Ventures 2019-05-30
Verdel Instruments–SEVERAL: investment, 201905 seed financing round £230k from Longwall Venture Partners + Innovate UK 2019-05-30
Verdel Instruments–United Kingdom (govt): investment, 201905 seed financing round totalling £230k incl investor Innovate UK 2019-05-30
Oxford BioMedica–Novo Group: investment, 201905–201906 investment £45.3m + optional £8.2m with 6.6m+1.2m new shares at £6.9/share 2019-05-28
JnJ–Owlstone: breath analyser, 201905– collab developm breath-based test for early detection of pulmonary hypertension with Actelion 2019-05-20
LifeArc–CPPIB: pembrolizumab, 201905 acquisition of portion of Keytruda royalty interests for $1.297b by CPPIB Credit Europe Sàrl 2019-05-20
Storm Therapeutics–Cambridge Innovation Capital: investment, 201905 financing round Series A extension totalling £14m incl existing investor CIC 2019-05-20
Storm Therapeutics–IP Group: investment, 201905 financing Series A extension totalling £14m incl existing investor IP Group 2019-05-20
Storm Therapeutics–Merck (DE): investment, 201905 financing round Series A extension totalling £14m incl existing investor M Ventures 2019-05-20
Storm Therapeutics–Otsuka: investment, 201905 financing Series A extension totalling £14m incl existing investor Taiho Ventures 2019-05-20
Storm Therapeutics–Pfizer: investment, 201905 financing round Series A extension totalling £14m incl existing investor Pfizer Ventures 2019-05-20
Storm Therapeutics–Seroba: investment, 201905 financing round Series A extension totalling £14m incl new investor Seroba Life Sciences 2019-05-20
Storm Therapeutics–SEVERAL: investment, 201905 financing round Series A extension £14m bringing total round to £30m incl new investor Seroba LS 2019-05-20
MeiraGTx–Bank of America: investor conference, 201905 supply service MeiraGTx presents at BoAML Global Healthcare Conference in Las Vegas 2019-05-15
Symphogen–SEVERAL: investment, 201905– capital increase up to DKK572m incl DKK182m debt conversion from existing shareholders 2019-05-15
United Kingdom (govt)–Congenica: bioinformatics, 201905 supply existent processing of samples for 100,000 Genomes Project for Genomics England 2019-05-14
Philogen–Consilium: public relations, 201905 service existent by CSC 2019-05-13
TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA 2019-05-13
Therachon–Novo Group: investment, 201905 existing investor Novo Holdings 2019-05-08
OMass–DyNAbind: drug discovery technology, 201905 collab existent with OMass Therapeutics 2019-05-07
Sosei–DyNAbind: drug discovery technology, 201905 collab existent with Sosei Heptares 2019-05-07
Abide Therapeutics–Lundbeck: investment, 201905– acquisition $250m upfront + $150m milestones of Abide by Lundbeck 2019-05-06
AstraZeneca–Transgene: cancer immunotherapy, 201905– collab + license option $10m upfront developm armed oncolytic vaccinia viruses using Invir.IO 2019-05-02
Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson 2019-05-02
Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif 2019-04-30
Enzyre–Optimum Strategic Communications: public relations, 201904 service existent by Optimum 2019-04-30
Poseida Therapeutics–Malin Corp: investment, 201904 financing round Series C totalling $142m incl existing + co-investor Malin Corp 2019-04-22
Boehringer–PureTech Health: cancer immunotherapy, 201904– colllab research up to $226m + royalties using lymphatic targeting platform for I-O drugs 2019-04-17
Gilead–Novo Group: drug development, 201904– collab clinical research for NASH combining semaglutide + cilofexor + firsocostat Novo Nordisk 2019-04-12
Uniqure–HC Wainwright: investor conference, 201904 supply service Uniqure attends HC Wainwright Global Life Sciences Conference in London 2019-04-09
Celyad–HC Wainwright: investor conference, 201904 supply service Celyad presents at HC Wainwright Global Life Sciences Conference in London 2019-04-08
4SC–HC Wainwright: investor conference, 201904 supply service 4SC presents at HC Wainwright Global Life Sciences Conference in London 2019-04-07
Gesynta Pharma–SEVERAL: investment, 201904 financing round €6m led by Industrifonden + incl group of private life science investors 2019-04-04
Gesynta Pharma–Sweden (govt): investment, 201904 financing round totalling €6m incl lead investor Industrifonden 2019-04-04
AgomAb Therapeutics–Instinctif Partners: public relations, 201901 service existent by Instinctif für UK + RoW 2019-04-03
Chr Hansen–Lonza: live biotherapeutics, 201904– collab establishment 50/50 joint venture for developing + manufacturing microbiome treatments 2019-04-02
Cambridge Innovation Capital–SEVERAL: investment, 201904 financing round £150m with Univ Cambridge as cornerstone investor 2019-04-01
Cambridge Innovation Capital–Univ Cambridge: investment, 201904 financing round totalling £150m incl cornerstone investor Univ Cambridge 2019-04-01
Digital China Health–Congenica: bioinformatics, 201904 collab existent DCH is commercial partner for Sapientia s/w in China 2019-04-01
Karuna–PureTech Health: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor PureTech Health 2019-04-01
Karuna–Wellcome Trust: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor Wellcome Trust 2019-04-01
Mogrify–United Kingdom (govt): grant, 201904 SBRI Healthcare funding for developm of cell therapy for osteoarthritis 2019-04-01
Cellnovo–NONE: investment, 201903 in administration 2019-03-28
Inivata–Consilium: public relations, 201903 service existent by CSC 2019-03-28
Inivata–LifeSci: public relations, 201903 service existent IR by LifeSci Advisors 2019-03-28
Univ College London–ArcherDx: PCR technology, 201903– collab €na use of AMP technology in UCL-sponsored UK lung cancer diagnostics TRACERx study 2019-03-28
Lundbeck–Enamine: chemical compound libraries, 201903– supply expansion discovery chemistry services by Enamine 2019-03-26
Exscientia–Edelman: public relations, 201803 service existent by Edelman PR 2019-03-22
Celgene–Exscientia: drug discovery software, 201903–202203 collab $25m upfront + milestones + royalties 3y AI drug discovery partnership 2019-03-21
United Kingdom (govt)–Cambridge Cancer Genomics: personalised immuno-oncology, 201903– collab long-term of Genomics England + CCG.ai 2019-03-21
Verona Pharma–ICR: public relations, 201903 service existent by ICR in US 2019-03-21
Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc 2019-03-21
NeoPhore–Optimum Strategic Communications: public relations, 201903 service existent by Optimum 2019-03-20
Oncimmune–Consilium: public relations, 201903 service existent by CSC 2019-03-19
Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen 2019-03-19
Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares 2019-03-19
Mogrify–United Kingdom (govt): grant, 201903 Innovate UK funding £420k to use big data analysis to advance cell therapies 2019-03-18
Metrion Biosciences–o2h: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Metrion Biosciences–SEVERAL: investment, 201903 financing round incl o2h Ventures Therapeutics Fund 2019-03-14
Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectos by MolMed for three new indications 2019-03-13
Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri 2019-03-12
Biogen–Fujifilm: investment, 201903– acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark 2019-03-12
MeiraGTx–Barclays: investor conference, 201903 supply service MeiraGTx presents at Barclays Global Healthcare Conference 2019-03-12
Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors 2019-03-12
AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies 2019-03-11
Orchard Therapeutics–Cowen: investor conference, 201903 supply service Orchard presents at Cowen & Co Annual Health Care Conference 2019 2019-03-11
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Lundbeck: investment, 201903 financing round Series A totalling $50m incl existing + co-lead investor Lundbeckfonden Emerge 2019-03-11
Snipr Biome–North-East Family Office: investment, 201903 financing round Series A totalling $50m incl co-investor North-East Family Office 2019-03-11
Snipr Biome–SEVERAL: investment, 201903 financing round Series A $50m co-led by Lundbeckfonden Emerge + Life Sciences Partners 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs 2019-03-04
Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED 2019-03-04
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
JnJ–AdoRx: adenosine receptor antagonists, 201902– collab developm + excl option €na lung cancer drugs with JnJ Innovation 2019-02-28
CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio 2019-02-27
MeiraGTx–683 Capital Management: investment, 201902 private placement totalling $80m incl co-investor 683 Capital Management 2019-02-27
MeiraGTx–JnJ: investment, 201902 private placement totalling $80m incl $40m from lead investor JJDC Inc 2019-02-27
MeiraGTx–Orbimed: investment, 201902 private placement totalling $80m incl co-investor Orbimed Advisors 2019-02-27
MeiraGTx–Perceptive Advisors: investment, 201902 private placement totalling $80m incl co-investor Perceptive Advisors 2019-02-27
MeiraGTx–SEVERAL: investment, 201902 private placement $80m with 5.8m ordinary shares at $13.8/share led by JJDC Inc 2019-02-27
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Mobidiag–Consilium: public relations, 201902 service existent by CSC 2019-02-25
Danaher–Barclays: investor conference, 201902 supply service Danaher presents at Barclays Industrial Select Conference in Miami 2019-02-20
Mogrify–24Haymarket: investment, 201902 seed financing round totalling $3.7m incl co-investor 24Haymarket 2019-02-20
Mogrify–Ahren Innovation Capital: investment, 201902 seed financing round totalling $3.7m incl existing + lead investor Ahren Innovation Capital 2019-02-20
Mogrify–PERSON: investment, 201902 seed financing round totalling $3.7m incl co-investor Darrin M Disley 2019-02-20
Mogrify–SEVERAL: investment, 201902 seed financing round $3.7m led by Ahren Innovation Capital + incl 24Haymarket + Darrin Disley 2019-02-20
Mogrify–Zyme Communications: public relations, 201902 service existent by Zyme 2019-02-20
Sygnature Discovery–BioStrata: public relations, 201902 service existent by BioStrata 2019-02-15
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Grey Wolf Therapeutics–Consilium: public relations, 201902 service existent by CSC 2019-02-11
Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan 2019-02-11
Pathios Therapeutics–Sygnature Discovery: drug discovery services, 201902– collab service discovery for GPCR target in autoimmune diseases + cancer 2019-02-07
United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS 2019-02-04
JnJ–MeiraGTx: gene therapy, 201901– collab r+d + license ww excl $100m upfront + milestones + funding + 20% royalties for inherited retinals diases 2019-01-31
Horizon Discovery–Rutgers Univ: gene editing technology, 201901– collab strategic developm + excl license option for base editing technology 2019-01-28
Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group 2019-01-22
1 2 3 ... 29 30 31  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px

» top